BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-α inhibitors

Introduction Obesity is an emerging phenomenon among patients with inflammatory bowel disease (IBD). This study aims to evaluate whether the response to tumour necrosis factor-α (TNF-α) inhibitors (infliximab and adalimumab) could be influenced by BMI in IBD. Methods We identified a cohort of 181 IBD patients attending a single-tertiary centre, naive to biologic therapy and stratified them according to their BMI. The primary outcome is the first occurrence of loss of response (LOR). Results The median BMI was 26 kg/m 2 (15–63 kg/m 2 ). Approximately 68% of patients had LOR on both adalimumab (ADA) ( n = 52) and infliximab (IFX) ( n = 71). However, 83% on ADA with BMI ≥30 kg/m 2 had LOR compared to 61% on IFX with BMI ≥30 kg/m 2 . For patients on ADA, Cox regression analysis revealed that after accounting for age, sex, disease type, duration of disease, fistulising disease, smoking status, haemoglobin, C-reactive protein, albumin and platelet levels, there were statistically significant associations between BMI (≥30 kg/m 2 vs. <30 kg/m 2 ) and LOR [ P = 0.010; hazard ratio (HR) 3.2; confidence interval (CI), 1.3–7.6]. However, for patients on IFX, after accounting for the same factors, the only significant factor was the association of lower rate of LOR with higher albumin levels ( P = 0.024; HR 0.95; CI, 0.91–0.99). There was an increased accelerated time to LOR for patients on ADA with BMI ≥30 kg/m 2 compared to BMI <30 kg/m 2 ( P = 0.026). However, there was no difference in time to LOR for patients on IFX ( P = 0.177). Conclusion BMI is important in predicting the LOR among IBD patients on TNF-α inhibitors, especially among patients receiving ADA.